kamada ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline. the company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce alpha-1 antitrypsin (aat) in a highly-purified, liquid form, as well as other plasma-derived proteins. aat is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. the company’s flagship product is glassia®, the first and only liquid, ready-to-use, intravenous plasma-derived aat product approved by the u.s. food and drug administration. kamada markets glassia in the u.s. through a strategic partnership with baxter international. in addition to glassia, kamada has a product line of nine other pharmaceutical products that are marketed through distributor
Company profile
Ticker
KMDA
Exchange
Website
CEO
Amir London
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
KMDA stock data
Latest filings (excl ownership)
6-K
Report of Foreign Private Issuer
6 Mar 24
20-F
2023 FY
Annual report (foreign)
6 Mar 24
6-K
Report of Foreign Private Issuer
28 Feb 24
6-K
Report of Foreign Private Issuer
28 Dec 23
6-K
Report of Foreign Private Issuer
6 Dec 23
6-K/A
Notice of Annual General Meeting of Shareholders
13 Nov 23
6-K
Notice of Annual General Meeting of Shareholders
13 Nov 23
6-K
Report of Foreign Private Issuer
13 Nov 23
6-K
Report of Foreign Private Issuer
8 Nov 23
6-K
Report of Foreign Private Issuer
16 Oct 23
Transcripts
KMDA
Earnings call transcript
2023 Q4
6 Mar 24
KMDA
Earnings call transcript
2023 Q3
13 Nov 23
KMDA
Earnings call transcript
2023 Q2
16 Aug 23
KMDA
Earnings call transcript
2023 Q1
24 May 23
KMDA
Earnings call transcript
2022 Q4
15 Mar 23
KMDA
Earnings call transcript
2022 Q3
22 Nov 22
KMDA
Earnings call transcript
2022 Q2
17 Aug 22
KMDA
Earnings call transcript
2022 Q1
17 May 22
KMDA
Earnings call transcript
2021 Q4
15 Mar 22
KMDA
Earnings call transcript
2021 Q3
22 Nov 21
Latest ownership filings
SC 13G/A
Gov Financial Holdings Ltd.
14 Feb 24
SC 13G/A
Phoenix Holdings Ltd.
12 Feb 24
SC 13G/A
Phoenix Holdings Ltd.
28 Dec 23
SC 13G/A
Phoenix Holdings Ltd.
19 Dec 23
SC 13D/A
DAVIDI ISHAY
7 Sep 23
SC 13D/A
DAVIDI ISHAY
24 May 23
SC 13G/A
Phoenix Holdings Ltd.
14 Feb 23
SC 13G/A
Phoenix Holdings Ltd.
7 Feb 22
SC 13G/A
Phoenix Holdings Ltd.
9 Nov 21
SC 13G/A
Hahn Jonathan
16 Feb 21
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
43.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 28 |
Opened positions | 6 |
Closed positions | 4 |
Increased positions | 8 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 23.21 bn |
Total shares | 24.88 mm |
Total puts | 10.10 k |
Total calls | 0.00 |
Total put/call ratio | Infinity |
Largest owners | Shares | Value |
---|---|---|
Davidi Ishay | 12.63 mm | $0.00 |
Gov Financial | 2.90 mm | $18.76 mm |
PXGPE Phoenix | 2.11 mm | $11.24 bn |
Hahn Jonathan | 1.90 mm | $12.34 mm |
Brosh Capital Partners | 1.73 mm | $11.86 mm |
Vanguard | 1.02 mm | $5.46 bn |
Renaissance Technologies | 866.51 k | $4.63 mm |
WFC Wells Fargo & Co. | 649.62 k | $3.50 bn |
Acadian Asset Management | 523.82 k | $2.82 mm |
Altshuler Shaham | 265.27 k | $1.42 bn |